Get the content you want anytime you want.

First Therapeutic Vaccine for Genital Herpes Reduces Signs of Infection for One Year

JUN 22, 2016 | SARAH ANWAR
Dr. Fife presented his team’s research at the ASM Microbe 2016 Conference, in Boston, Massachusetts. Their clinical trial included 310 participants known to have chronic, recurrent genital herpes. The patients were injected with six different doses of the three injections, 21 days apart. Over the course of one year, patients were tested for signs of body response to the herpes virus, whether through visible signs of viral shedding, lesions, or immune response to the virus. The frequency of observable signs of the virus significantly decreased after treatment with GEN-003, while immune response data is still under analysis.
Dr. Fife explained GEN-003’s functions to Contagion.

Big advances in treatment can